Literature DB >> 10762185

Midodrine hydrochloride and the treatment of orthostatic hypotension in tetraplegia: two cases and a review of the literature.

D B Barber1, S J Rogers, M D Fredrickson, A C Able.   

Abstract

STUDY
DESIGN: A report of two cases of orthostatic hypotension in acute tetraplegia that were resistant to classic treatment interventions.
OBJECTIVE: To discuss the use of midodrine hydrochloride for the treatment of orthostatic hypotension in early tetraplegia.
SETTING: Department of Rehabilitation Medicine, The University of Texas Health Science Center at San Antonio, Texas, USA.
METHODS: Presentation of two cases.
RESULTS: Midodrine hydrochloride successfully treated two cases of orthostatic hypotension that had been refractory to classic treatment interventions.
CONCLUSION: Midodrine hydrochloride should be included in the armamentarium of the physician treating orthostatic hypotension in spinal cord injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10762185     DOI: 10.1038/sj.sc.3100959

Source DB:  PubMed          Journal:  Spinal Cord        ISSN: 1362-4393            Impact factor:   2.772


  10 in total

1.  Improvements in orthostatic instability with stand locomotor training in individuals with spinal cord injury.

Authors:  Susan J Harkema; Christie K Ferreira; Rubia J van den Brand; Andrei V Krassioukov
Journal:  J Neurotrauma       Date:  2008-12       Impact factor: 5.269

2.  Effect of Alpha-1-Adrenergic Agonist, Midodrine for the Management of Long-Standing Neurogenic Shock in Patient with Cervical Spinal Cord Injury: A Case Report.

Authors:  Taikwan Kim; Cheol Su Jwa
Journal:  Korean J Neurotrauma       Date:  2015-10-31

3.  Lessons learned from the pilot study of an orthostatic hypotension intervention in the subacute phase following spinal cord injury.

Authors:  Bastien Moineau; Andrea Brown; Louise Brisbois; Vera Zivanovic; Masae Miyatani; Naaz Kapadia; Jane T C Hsieh; Milos R Popovic
Journal:  J Spinal Cord Med       Date:  2019-10       Impact factor: 1.985

4.  Normalization of supine blood pressure after nitric oxide synthase inhibition in persons with tetraplegia.

Authors:  Jill M Wecht; Joseph P Weir; AnnMarie H Krothe; Ann M Spungen; William A Bauman
Journal:  J Spinal Cord Med       Date:  2007       Impact factor: 1.985

5.  Refractory orthostatic hypotension in a patient with a spinal cord injury: Treatment with droxidopa.

Authors:  Eva Canosa-Hermida; Cristina Mondelo-García; María Elena Ferreiro-Velasco; Sebastián Salvador-de la Barrera; Antonio Montoto-Marqués; Antonio Rodríguez-Sotillo; José Ramón Vizoso-Hermida
Journal:  J Spinal Cord Med       Date:  2017-01-24       Impact factor: 1.985

6.  Comparative Clinical Pharmacokinetics of Midodrine and Its Active Metabolite Desglymidodrine in Cirrhotic Patients with Tense Ascites Versus Healthy Volunteers.

Authors:  Ahmed Ali; Samar Farid; Mona Amin; Mohamed Kassem; Nouman Al-Garem; Medhat Al-Ghobashy
Journal:  Clin Drug Investig       Date:  2016-02       Impact factor: 2.859

Review 7.  A systematic review of the management of orthostatic hypotension after spinal cord injury.

Authors:  Andrei Krassioukov; Janice J Eng; Darren E Warburton; Robert Teasell
Journal:  Arch Phys Med Rehabil       Date:  2009-05       Impact factor: 3.966

Review 8.  Vascular dysfunctions following spinal cord injury.

Authors:  Constantin Popa; Florian Popa; Valentin Titus Grigorean; Gelu Onose; Aurelia Mihaela Sandu; Mihai Popescu; Gheorghe Burnei; Victor Strambu; Crina Sinescu
Journal:  J Med Life       Date:  2010 Jul-Sep

Review 9.  Cardiac dysfunctions following spinal cord injury.

Authors:  Valentin Titus Grigorean; Aurelia Mihaela Sandu; Mihai Popescu; Mihai Aurelian Iacobini; Rares Stoian; Catalin Neascu; Victor Strambu; Florian Popa
Journal:  J Med Life       Date:  2009 Apr-Jun

10.  Management of Hypotension and Bradycardia Caused By Spinal Cord Injury. The Usefulness of Midodrine and Methylxanthines.

Authors:  Mojtaba Mojtahedzadeh; Hamidreza Taghvaye-Masoumi; Atabak Najafi; Mehrnoush Dianatkhah; Hamidreza Sharifnia; Maryam Shahrokhi
Journal:  Iran J Pharm Res       Date:  2019       Impact factor: 1.696

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.